Literature DB >> 12819059

Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine.

Elisabeth Wedege1, Betsy Kuipers, Karin Bolstad, Harry van Dijken, L Oddvar Frøholm, Clementien Vermont, Dominique A Caugant, Germie van den Dobbelsteen.   

Abstract

Antibody specificities of pre- and postvaccination serum samples from 40 (53%) teenagers who received three doses of the Norwegian Neisseria meningitidis serogroup B vaccine (B:15:P1.7,16) during a previous trial in Iceland (Perkins et al., J. Infect. Dis. 177:683-691, 1998) were analyzed with serum bactericidal activity (SBA) and immunoblotting assays with reference and isogenic meningococcal H44/76 vaccine strains. The H44/76 variants demonstrated significant vaccine-induced SBA to P1.7,16 PorA and Opc but not to PorB, Opa5.5, and a heterologous PorA protein. On blots, immunoglobulin G levels to all these proteins increased significantly after vaccination. Measurement of SBA to the two main variable regions (P1.7 and P1.16) on the P1.7,16 PorA with PorA deletion mutants revealed significantly higher activity to the P1.7,- and P1.-,16 mutants compared to the P1.7,16 strain, indicating exposure of new accessible epitopes. Only 12 (30%) serum samples showed distinct decreases with these or the P1.-,- mutant, with most samples containing SBA to the P1.7 and P1.16 combination. In contrast, P1.16-specific antibodies were mainly found on blots. Thirteen of the vaccinees (32.5%) were carriers of meningococci at the time of the third dose, of whom four (30.8%) harbored strains of the ET-5 complex. Carriage of P1.15 strains was generally reflected in > or =4-fold increases in SBA and distinct immunoglobulin G binding to the P1.19,15 PorA on blots. Although vaccination did not elicit bactericidal activity to the serotype 15 PorB, most carriers of serotype 15 strains showed > or =4-fold increases in SBA to this antigen.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12819059      PMCID: PMC162037          DOI: 10.1128/IAI.71.7.3775-3781.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  Genetic and immunologic characterization of a novel serotype 4, 15 strain of Neisseria meningitidis.

Authors:  M C Bash; F Lynn; N F Concepcion; J W Tappero; G M Carlone; C E Frasch
Journal:  FEMS Immunol Med Microbiol       Date:  2000-11

2.  PorB3 outer membrane protein on Neisseria meningitidis is poorly accessible for antibody binding on live bacteria.

Authors:  T E Michaelsen; A Aase; J Kolberg; E Wedge; E Rosenqvist
Journal:  Vaccine       Date:  2001-01-08       Impact factor: 3.641

3.  Phylogenetic evidence for frequent positive selection and recombination in the meningococcal surface antigen PorB.

Authors:  Rachel Urwin; Edward C Holmes; Andrew J Fox; Jeremy P Derrick; Martin C J Maiden
Journal:  Mol Biol Evol       Date:  2002-10       Impact factor: 16.240

4.  Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine.

Authors:  S L Martin; R Borrow; P van der Ley; M Dawson; A J Fox; K A Cartwright
Journal:  Vaccine       Date:  2000-05-22       Impact factor: 3.641

5.  Circumvention of herd immunity during an outbreak of meningococcal disease could be correlated to escape mutation in the porA gene of Neisseria meningitidis.

Authors:  M K Taha; E Bichier; A Perrocheau; J M Alonso
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

6.  IgG antibody levels to meningococcal porins in patient sera: comparison of immunoblotting and ELISA measurements.

Authors:  E Wedege; K Bolstad; L M Wetzler; H Guttormsen
Journal:  J Immunol Methods       Date:  2000-10-20       Impact factor: 2.303

7.  Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.

Authors:  J C de Moraes; B A Perkins; M C Camargo; N T Hidalgo; H A Barbosa; C T Sacchi; I M Landgraf; V L Gattas; H de G Vasconcelos; I M Gral
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321

8.  Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis.

Authors:  J Claire Wright; Jeannette N Williams; Myron Christodoulides; John E Heckels
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

9.  Characterization of humoral and cellular immune responses elicited by meningococcal carriage.

Authors:  K Robinson; K R Neal; C Howard; J Stockton; K Atkinson; E Scarth; J Moran; A Robins; I Todd; E Kaczmarski; S Gray; I Muscat; R Slack; D A A Ala'Aldeen
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  8 in total

1.  Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.

Authors:  E Wedege; K Bolstad; A Aase; T K Herstad; L McCallum; E Rosenqvist; P Oster; D Martin
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

2.  Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.

Authors:  Maija Toropainen; Leena Saarinen; Elisabeth Wedege; Karin Bolstad; Terje E Michaelsen; Audun Aase; Helena Käyhty
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

3.  Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteins.

Authors:  Tathagat Dutta Ray; Lisa A Lewis; Sunita Gulati; Peter A Rice; Sanjay Ram
Journal:  J Immunol       Date:  2011-03-14       Impact factor: 5.422

4.  Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.

Authors:  Jamie Findlow; Stephen Taylor; Audun Aase; Rachel Horton; Robert Heyderman; Jo Southern; Nick Andrews; Rita Barchha; Ewan Harrison; Ann Lowe; Emma Boxer; Charlotte Heaton; Paul Balmer; Ed Kaczmarski; Philipp Oster; Andrew Gorringe; Ray Borrow; Elizabeth Miller
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

5.  Stability of PorA during a meningococcal disease epidemic.

Authors:  A F Devoy; K H Dyet; D R Martin
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

6.  A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.

Authors:  L Marsay; C Dold; C A Green; C S Rollier; G Norheim; M Sadarangani; M Shanyinde; C Brehony; A J Thompson; H Sanders; H Chan; K Haworth; J P Derrick; I M Feavers; M C Maiden; A J Pollard
Journal:  J Infect       Date:  2015-05-15       Impact factor: 6.072

Review 7.  Recent Progress in the Prevention of Serogroup B Meningococcal Disease.

Authors:  Ian M Feavers; Martin C J Maiden
Journal:  Clin Vaccine Immunol       Date:  2017-05-05

8.  Effect of Vaccine-Elicited Antibodies on Colonization of Neisseria meningitidis Serogroup B and C Strains in a Human Bronchial Epithelial Cell Culture Model.

Authors:  Vianca Vianzon; Beate Illek; Gregory R Moe
Journal:  Clin Vaccine Immunol       Date:  2017-10-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.